Design Therapeutics (DSGN) Preferred Stock Liabilities (2020)
Design Therapeutics recorded quarterly Preferred Stock Liabilities of $45.4 million in Q4 2020, little changed quarter-over-quarter from $45.4 million in Q3 2020.
Design Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $45.4 million for Q4 2020.
- In Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $45.4 million; the TTM figure through Dec 2020 stood at $45.4 million (changed N/A YoY), while the FY2020 annual figure was $45.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $45.4 million for Q4 2020 at Design Therapeutics, roughly flat from $45.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $45.4 million in Q1 2020 to a low of $45.4 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 45.36 Mn |
| Sep 30, 2020 | 45.36 Mn |
| Jun 30, 2020 | 45.36 Mn |
| Mar 31, 2020 | 45.36 Mn |